ZKHF 002
Alternative Names: ZKHF-002Latest Information Update: 09 Jun 2022
At a glance
- Originator Zhaoke Pharmaceutical (Hefei)
- Developer Lee's Pharmaceutical; Zhaoke Pharmaceutical (Hefei)
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Cardiovascular disorders
Most Recent Events
- 09 Jun 2022 Preregistration for Cardiovascular disorders in China (unspecified route) before June 2022 (Lee's Pharma pipeline, June 2022)
- 10 Dec 2020 Preclinical trials in Cardiovascular disorders in China (unspecified route) before December 2020 (Lee's pharmaceutical pipeline, December 2020)